TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05482893: Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including G

Sponsor: Phanes Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 350 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05482893 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05482893 Rescue Dossier →